Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Vegter, N. Nguyen, S. Visser, L. Berg, M. Postma, C. Boersma (2011)Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.
The American journal of managed care, 17 9
H Enlund (1982)Measuring patient compliance in antihypertensive therapy?some methodological aspects
J Clin Hosp Pharm, 7
Karen McClellan, Karen Goa (1998)Candesartan Cilexetil
S. Mochizuki, B. Dahlöf, M. Shimizu, K. Ikewaki, M. Yoshikawa, I. Taniguchi, M. Ohta, Taku Yamada, K. Ogawa, K. Kanae, M. Kawai, S. Seki, F. Okazaki, M. Taniguchi, S. Yoshida, N. Tajima (2007)RETRACTED: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study
The Lancet, 369
J. Gillis, A. Markham (2012)Irbesartan
W. Elliott (2010)Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study
Yearbook of Cardiology, 2010
(2003)treatment of high blood pressure: the JNC 7 report
G. Mancia, G. Backer, A. Dominiczak, R. Cífková, R. Fagard, G. Germano, G. Grassi, A. Heagerty, S. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R. Schmieder, H. Boudier, A. Zanchetti (2007)2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Journal of Hypertension, 25
G. Aulakh, R. Sodhi, M. Singh (2007)An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
Life sciences, 81 8
W. White, M. Weber, D. Sica, G. Bakris, Alfonso Perez, Charlie Cao, S. Kupfer (2011)Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension
P. Blankestijn, H. Rupp (2008)Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
Cardiovascular & Hematological Agents in Medicinal Chemistry, 6
S. Yi, Tae-Eun Kim, S. Yoon, Joo-Youn Cho, Sang‐Goo Shin, I. Jang, K. Yu (2011)Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, With Amlodipine in Healthy Volunteers
Journal of Cardiovascular Pharmacology, 57
(2007)Azilsartan medoxomil (Edarbi) for hypertension
A. Tykarski, Krzysztof Narkiewicz, Zbigniew Gaciong, A. Januszewicz, M. Litwin, Katarzyna Kostka-Jeziorny (2015)Guidelines for the Management of Hypertension
Arterial Hypertension, 19
S. Yusuf, Iyad Daher (2008)Thrombolytics for PE and right ventricular dysfunction
The Lancet, 372
S. Yusuf, K. Teo, C. Anderson, J. Pogue, L. Dyal, I. Copland, H. Schumacher, Dagenais Gr, P. Sleight (2008)Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
The Lancet, 372
T. Sawada, H. Yamada, B. Dahlöf, H. Matsubara (2013)Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study [Eur Heart J (2009) 30:2461-2469, doi: 10.1093/eurheartj/ehp363].
European heart journal, 34 14
Ruth Wexler, W. Greenlee, John Irvin, Michael Goldberg, Kristine Prendergast, Ronald Smith, Pieter Timmermans (1996)Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, 39 3
J. Nagel, A. Tietz, B. Göke, K. Parhofer (2006)The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.
Metabolism: clinical and experimental, 55 9
D. Sica, H. Black (2002)ACE Inhibitor‐Related Angioedema: Can Angiotensin‐Receptor Blockers Be Safely Used?
The Journal of Clinical Hypertension, 4
Tae Kim, B. Yoo, J. Lee, Ji Kim, Kyung-Tae Lee, Y. Chi, J. Lee (2012)Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.
Bioorganic & medicinal chemistry letters, 22 4
SE Lee, YJ Kim, HY Lee (2012)Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100�mg): A 12-week, Phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension
Clin Ther, 34
G. Mancia, G. Backer, A. Dominiczak, R. Cífková, R. Fagard, G. Germano, G. Grassi, A. Heagerty, S. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R. Schmieder, H. Boudier, A. Zanchetti, A. Vahanian, J. Camm, R. Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. Kristensen, K. Mcgregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. Zamorano, S. Erdine, W. Kiowski, E. Agabiti-Rosei, E. Ambrosioni, L. Lindholm, G. Mancia, A. Manolis, P. Nilsson, J. Redón, H. Struijker-Boudier, M. Viigimaa, S. Adamopoulos, V. Bertoméu, D. Clement, C. Farsang, D. Gaita, G. Lip, J. Mallion, A. Manolis, E. O’Brien, P. Ponikowski, F. Ruschitzka, J. Tamargo, P. Zwieten, B. Waeber, B. Williams, The hype (2007)2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
European heart journal, 28 12
T Ogihara, K Kikuchi, H Matsuoka (2009)Japanese Society of Hypertension committee. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009)
Hypertens Res, 32
J. Neutel, David Smith (2003)Evaluation of Angiotensin II Receptor Blockers for 24‐Hour Blood Pressure Control: Meta‐Analysis of a Clinical Database
The Journal of Clinical Hypertension, 5
H. Gavras, A. Flessas, T. Ryan, H. Brunner, D. Faxon, I. Gavras (1977)Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension.
JAMA, 238 8
Sang Lee, Yong-Jin Kim, Hae-Young Lee, Han-Mo Yang, C. Park, Jae-Joong Kim, Soon-Kil Kim, M. Rhee, B. Oh (2012)Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients
Clinical therapeutics, 34 3
S. Wassmann, G. Nickenig (2004)The role of the AT1 receptor in the cardiovascular continuum
European Heart Journal, 6
T. Ogihara, K. Kikuchi, H. Matsuoka, T. Fujita, J. Higaki, M. Horiuchi, Y. Imai, T. Imaizumi, S. Ito, H. Iwao, K. Kario, Y. Kawano, S. Kim‐Mitsuyama, G. Kimura, H. Matsubara, Hideo Matsuura, M. Naruse, I. Saito, K. Shimada, K. Shimamoto, Hiromichi Suzuki, S. Takishita, N. Tanahashi, T. Tsuchihashi, M. Uchiyama, S. Ueda, H. Ueshima, S. Umemura, T. Ishimitsu, H. Rakugi (2009)The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)—Chapter 2
Hypertension Research, 32
Safety and Efficacy of Fimasartan
J. Wogen, Charles Krelick, R. Livornese, K. Yokoyama, F. Frech (2003)Patient Adherence With Amlodipine, Lisinopril, or Valsartan Therapy in a Usual-Care Setting
Journal of Managed Care Pharmacy : JMCP, 9
G. Mancia, R. Fagard, K. Narkiewicz, J. Redón, A. Zanchetti, M. Böhm, T. Christiaens, R. Cífková, G. Backer, A. Dominiczak, M. Galderisi, D. Grobbee, T. Jaarsma, P. Kirchhof, S. Kjeldsen, S. Laurent, A. Manolis, P. Nilsson, L. Ruilope, R. Schmieder, P. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad (2007)2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Journal of hypertension, 31 7
D. Sica, A. Schoolwerth (2002)Part 1. Uric acid and losartan
Current Opinion in Nephrology and Hypertension, 11
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
JAMA, 289 19
M. Strauss, A. Hall (2010)Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study.
European heart journal, 31 2
T. Ogihara, K. Kikuchi, H. Matsuoka, Toshiro Fujita, J. Higaki, M. Horiuchi, Yutaka Imai, T. Imaizumi, S. Ito, Hiroshi Iwao, K. Kario, Y. Kawano, S. Kim‐Mitsuyama, G. Kimura, Hiroaki Matsubara, Hideo Matsuura, M. Naruse, I. Saito, K. Shimada, K. Shimamoto, Hiromichi Suzuki, S. Takishita, N. Tanahashi, T. Tsuchihashi, M. Uchiyama, S. Ueda, H. Ueshima, S. Umemura, T. Ishimitsu, H. Rakugi (2009)The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
Hypertension Research, 37
JC Gillis, A Merkham (1997)Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
J. Basile (2009)Blood pressure responder rates versus goal rates: which metric matters?
Therapeutic Advances in Cardiovascular Disease, 3
S. Yusuf, K. Teo, J. Pogue, L. Dyal, I. Copland, H. Schumacher, G. Dagenais, P. Sleight, C. Anderson (2008)Telmisartan, ramipril, or both in patients at high risk for vascular events.
The New England journal of medicine, 358 15
Bret Haymore, Jiun Yoon, C. Mikita, M. Klote, Kent Dezee (2008)Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 101 5
W. Ahmad (2008)Effect of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial: The Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND)
H. Enlund (1982)MEASURING PATIENT COMPLIANCE IN ANTIHYPERTENSIVE THERAPY * —SOME METHODOLOGICAL ASPECTS
Journal of Clinical Pharmacy and Therapeutics, 7
W. Elliott (2008)Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study
Yearbook of Cardiology, 2008
K. McClellan, K. Goa (1998)Candesartan cilexetil. A review of its use in essential hypertension.
Drugs, 56 5
D. Sica, W. White, M. Weber, G. Bakris, Alfonso Perez, Charlie Cao, Alison Handley, S. Kupfer (2011)Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring
The Journal of Clinical Hypertension, 13
D. Choi, Seongwook Han, E. Jeon, M. Cho, Jae-Joong Kim, B. Yoo, M. Shin, I. Seong, Y. Ahn, Seok‐Min Kang, Yung-Jo Kim, Hyung Kim, S. Chae, B. Oh, Myung-Mook Lee, K. Ryu (2011)Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry
Korean Circulation Journal, 41
F. Zannad, R. Fay (2007)Blood pressure‐lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies
Fundamental & Clinical Pharmacology, 21
M. Mcintyre, S. Caffe, R. Michalak, J. Reid (1997)Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension.
Pharmacology & therapeutics, 74 2
DA Sica, HR Black (2002)Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?
J Clin Hypertens (Greenwich), 4
S. Oparil, David Williams, S. Chrysant, T. Marbury, J. Neutel (2001)Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension
The Journal of Clinical Hypertension, 3
Am J Cardiovasc Drugs (2013) 13:47–56 DOI 10.1007/s40256-013-0004-9 OR IGINAL RESEARCH ARTIC L E Safety and Efﬁcacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study) An Open-Label Observational Study • • • Jeong Bae Park Ki-Chul Sung Seok-Min Kang Eun Joo Cho Published online: 24 January 2013 The Author(s) 2013. This article is published with open access at Springerlink.com Abstract collected using electronic case report forms. Written Background Angiotensin II receptor blockers (ARBs) informed consent forms were obtained from all patients. play a key role in hypertension therapy. Recently, ﬁma- Results A total of 14,151 patients (50.7 % males; mean age sartan, the ninth ARB, was developed, but its safety and 59 ± 12 years) were evaluated, of whom 37.9 % were never efﬁcacy have not been well established. treated with ﬁmasartan, 53.5 % were switched to ﬁmasartan, Objective The objective of this study was to determine and 8.5 % had ﬁmasartan added to their treatment. Overall, whether age, sex, concomitant disease, and current anti- ﬁmasartan reduced systolic blood pressure (SBP) from hypertensive medications affect the safety and efﬁcacy of 145.4 ± 18.1 to 126.8 ± 12.6 mmHg and diastolic blood ﬁmasartan in patients with arterial hypertension. pressure
American Journal of Cardiovascular Drugs – Springer Journals
Published: Jan 24, 2013
Access the full text.
Sign up today, get DeepDyve free for 14 days.